Lexaria Bioscience Corp LEXX

Alternate Symbol(s): LEXXW

Biotechnology

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.

NDAQ:LEXX - Post by User

Lexaria Bioscience Corp

Bullboard Posts

Comment by shawkon Jan 19, 2017 12:31pm

154 Views

Post# 25728733

RE:NU finally broke out of 18

Yes, there are other products out there, but bioavailability and taste are two of the big problems which Lexaria has solved. CBD is broken down by stomach acids and the liver, LXRP's technology avoids this. Also Cannabinnoid extracts have a very strong taste so manufacturers add lots of sugar and flavors to mask the bad taste, again LXRP's technology solves this problem. The bonus is that it's really cost effective and could be used for other things such as nicotine and pharmaceuticals.

Bullboard Posts

Anaergia expands relationship with PepsiCo